PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPegloticase
Krystexxa(pegloticase)
Krystexxa (pegloticase) is an enzyme pharmaceutical. Pegloticase was first approved as Krystexxa on 2010-09-14. It is used to treat gout in the USA. It has been approved in Europe to treat gout.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Krystexxa
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pegloticase
Tradename
Proper name
Company
Number
Date
Products
KrystexxapegloticaseHorizon Therapeutics PublicN-125293 RX2010-09-14
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
krystexxaBiologic Licensing Application2025-08-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
goutEFO_0004274D006073M10
Agency Specific
FDA
EMA
Expiration
Code
pegloticase, Krystexxa, Horizon Therapeutics Ireland DAC
2117-09-14Orphan excl.
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M04: Antigout preparations
— M04A: Antigout preparations
— M04AX: Other antigout preparations in atc
— M04AX02: Pegloticase
HCPCS
Code
Description
J2507
Injection, pegloticase, 1 mg
Clinical
Clinical Trials
22 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GoutD006073EFO_0004274M10————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePegloticase
INNpegloticase
Description
Tetramer alpha4 of des-(1-5)-[6-threonine,45-threonine,290-lysine,300-serine]uricase (EC 1.7.3.3, urate oxidase) from Sus scrofa (porcine), non acetylated, of which some of the lysine 6-amine residues are engaged in a carbamate linkage with a monomethylic ether of polyoxyethylene (macrogol)
Classification
Enzyme
Drug classenzymes; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1237025
ChEBI ID—
PubChem CID—
DrugBankDB09208
UNII IDR581OT55EA (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Krystexxa – Horizon Therapeutics Public
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Krystexxa – Amgen
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 788 documents
View more details
Safety
Black-box Warning
Black-box warning for: Krystexxa
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,329 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use